An antibody treatment for Covid-19 that reportedly cuts hospitalisations and deaths by 78 per cent in clinical trials is expected to be approved for use in China within weeks. Chinese viral immunologist Zhang Linqi is the driving force behind the antiviral cocktail which was put together in about two months. But in an interview with state television on November 18, 2021, Zhang noted that years of research was behind the treatment which appears to be effective against all known variants of Covid-19 now present in China.